spacer
home > ebr > winter 2018 > discovery decisions
PUBLICATIONS
European Biopharmaceutical Review

Discovery Decisions

The discovery of new drugs is driven by data. The data generated on compounds’ activities – in combination with absorption, distribution, metabolism and elimination (ADME), physicochemical and safety properties – enable selection of compounds for progression to further study. These data are also used to identify relationships between the structures of compounds and their observed activities and properties – structure-activity relationships (SAR) – guiding the design of improved compounds against a project’s objectives. In accessing these data, time is of the essence; selecting compounds based on incomplete or out-of-date information or designing new compounds without the latest results can lead to wasted time and effort through redundant experiments being performed and poor compounds being synthesised.

Managing Data

Large pharma companies use sophisticated laboratory information management platforms to capture information and store the results in large databases or data ‘warehouses’. Entire departments are devoted to ensuring the coherence of these data because of their value to the company. Smaller organisations often do not have this luxury, and, in the worst cases, may have data from a variety of sources stored in individual files, in different locations and maintained by a range of scientists (often for their personal use). In the latter case, how much value is lost when data, often generated at high cost, are not available to the decision-makers in a project?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Matthew Segall has an MSc in computation from the University of Oxford, UK, and a PhD in theoretical physics from the University of Cambridge, UK. At Camitro, ArQule and Inpharmatica, Matt led a team developing predictive ADME models and intuitive decision-support tools for drug discovery. In 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director of BioFocus DPI’s ADMET division and, in 2009, founded Optibrium, which develops software for small molecule design, optimisation and data analysis. 

Dr Chris Leeding has a PhD in chemistry from King’s College, London, UK and his career has focused on scientific software development. Chris has worked on the development of StarDrop since 2006, most recently as Optibrium’s Director of Product Development, and taken a lead role in integrating StarDrop with customers’ database and informatics infrastructure.

spacer
Dr Matthew Segall
spacer
spacer
spacer
Dr Chris Leeding
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement